SHIP-1 Modulation in Experimental Allergic Conjunctivitis: Impact on CD4⁺ T Cell Migration

Area of Science:

• Immunology
• Ophthalmology
• Pharmacology

Background:

• Allergic conjunctivitis (EAC) involves complex immune responses.
• Src-homology 2 domain-containing inositol-5-phosphatase 1 (SHIP-1) plays a role in immune cell signaling.
• Understanding SHIP-1's function in EAC is crucial for developing targeted therapies.

Purpose of the Study:

• To investigate the role of SHIP-1 in experimental allergic conjunctivitis (EAC).
• To evaluate the therapeutic potential of SHIP-1 activators and antagonists in EAC.

Main Methods:

• A short ragweed-induced EAC mouse model was used.
• Mice received subconjunctival injections of SHIP-1 activator (AQX1125) or antagonist (3AC).
• Clinical symptoms, histopathology, immunofluorescence, protein expression (Western blotting), and splenic immune cell profiles (flow cytometry) were analyzed.

Main Results:

• AQX1125 significantly reduced ocular symptoms and disease duration compared to 3AC.
• Histopathology showed decreased inflammatory cell infiltration with AQX1125 treatment.
• AQX1125 suppressed CD4+ T cell recruitment and modulated PI3K/AKT/mTOR signaling, while 3AC had opposite effects.

Conclusions:

• SHIP-1 activation demonstrates anti-inflammatory properties in allergic conjunctivitis.
• SHIP-1 activators may be a promising therapeutic approach for EAC.
• Therapeutic effects are linked to suppressing pathogenic CD4+ T cell migration and modulating key signaling pathways.